1
|
Li M, Fang G, Zahid F, Saleem R, Ishrat G, Ali Z, Naeem M, Din FU. Co-delivery of paclitaxel and curcumin loaded solid lipid nanoparticles for improved targeting of lung cancer: In vitro and in vivo investigation. Heliyon 2024; 10:e30290. [PMID: 38720725 PMCID: PMC11076978 DOI: 10.1016/j.heliyon.2024.e30290] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2023] [Revised: 04/22/2024] [Accepted: 04/23/2024] [Indexed: 05/12/2024] Open
Abstract
The objective of this study was to develop nanotechnology-mediated paclitaxel (PAC) and curcumin (CUR) co-loaded solid lipid nanoparticles (PAC-CUR-SLNs) for the treatment of lung cancer, which is a leading cause of death worldwide. Around 85 % cases of lungs cancer constitute non-small cell lung cancer (NSCLC). PAC-CUR-SLNs were prepared via high pressure homogenization. The in vitro drug release of PAC-CUR-SLNs was checked followed by their in vitro cytotoxic investigation using adenocarcinomic human alveolar basal epithelial cells (A549) cell lines. Anticancer effects along with side effects of the synergistic delivery of PAC-CUR-SLNs were studied in vivo, using BALB/c mice. PAC-CUR-SLNs were nano sized (190 nm), homogeneously disseminated particles with %IE of both PAC and CUR above 94 %. PAC-CUR-SLNs released PAC and CUR in a controlled fashion when compared with free drug suspensions. The cytotoxicity of PAC-CUR-SLNs was higher than individual drug-loaded SLNs and pure drugs. Moreover, the co-delivery displayed synergistic effect, indicating potential of PAC-CUR-SLNs in lung cancer treatment. In vivo tumor investigation of PAC-CUR-SLNs exhibited 12-fold reduced tumor volume and almost no change in body weight of BALB/c mice, when compared with the experimental groups including control group. The inhibition of tumor rate on day 28 was 82.7 % in the PAC-CUR-SLNs group, which was significantly higher than the pure drugs and monotherapies. It can be concluded that, encapsulating the co-loaded antitumor drugs like PAC-CUR in SLNs may help in improved targeting of the tumor with enhanced anticancer effect.
Collapse
Affiliation(s)
- Mao Li
- Guangxi Higher Education Key Laboratory for the Research of Du-related Diseases in Zhuang Medicine, Guangxi University of Chinese Medicine, Nanning, 530001, China
| | - Gang Fang
- Guangxi Higher Education Key Laboratory for the Research of Du-related Diseases in Zhuang Medicine, Guangxi University of Chinese Medicine, Nanning, 530001, China
| | - Fatima Zahid
- Department of Pharmacy Quaid-i-Azam University, 45320, Islamabad, Pakistan
- Nanomedicine Research Group, Department of Pharmacy Quaid-i-Azam University, 45320, Islamabad, Pakistan
| | - Raheela Saleem
- College of Pharmacy, Liaquat University of Medical and Health Sciences Jamshoro, Pakistan
| | - Ghazala Ishrat
- Department of Pharmaceutics, Faculty of Pharmacy, Salim Habib University, Karachi, Pakistan
| | - Zakir Ali
- Department of Pharmacy Quaid-i-Azam University, 45320, Islamabad, Pakistan
- Nanomedicine Research Group, Department of Pharmacy Quaid-i-Azam University, 45320, Islamabad, Pakistan
| | - Muhammad Naeem
- National University of Medical Sciences, Rawalpindi, Pakistan
| | - Fakhar ud Din
- Department of Pharmacy Quaid-i-Azam University, 45320, Islamabad, Pakistan
- Nanomedicine Research Group, Department of Pharmacy Quaid-i-Azam University, 45320, Islamabad, Pakistan
| |
Collapse
|
2
|
Chhimwal J, Dhritlahre RK, Anand P, Ruchika, Patial V, Saneja A, Padwad YS. Amorphous solid dispersion augments the bioavailability of phloretin and its therapeutic efficacy via targeting mTOR/SREBP-1c axis in NAFLD mice. BIOMATERIALS ADVANCES 2023; 154:213627. [PMID: 37748276 DOI: 10.1016/j.bioadv.2023.213627] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/04/2023] [Revised: 09/14/2023] [Accepted: 09/15/2023] [Indexed: 09/27/2023]
Abstract
The escalating incidences of non-alcoholic fatty liver disease (NAFLD) and associated metabolic disorders are global health concerns. Phloretin (Ph) is a natural phenolic compound, that exhibits a wide array of pharmacological actions including its efficacy towards NAFLD. However, poor solubility and bioavailability of phloretin limits its clinical translation. Here, to address this concern we developed an amorphous solid dispersion of phloretin (Ph-SD) using Soluplus® as a polymer matrix. We further performed solid-state characterization through SEM, P-XRD, FT-IR, and TGA/DSC analysis. Phloretin content, encapsulation efficiency, and dissolution profile of the developed formulation were evaluated through reverse phase HPLC. Finally, the oral bioavailability of Ph-SD and its potential application in the treatment of experimental NAFLD mice was investigated. Results demonstrated that the developed formulation (Ph-PD) augments the dissolution profile and oral bioavailability of the native phloretin (Ph). In NAFLD mice, histopathological studies revealed the preventive effect of Ph-SD on degenerative changes, lipid accumulation, and inflammation in the liver. Ph-SD also improved the serum lipid profile, ALT, and AST levels and lowered the interleukin-6 and tumor necrosis factor-α levels in the liver. Further, Ph-SD reduced fibrotic changes in the liver tissues and attenuates NAFLD progression by blocking the mTOR/SREBP-1c pathway. In a nutshell, the results of our study strongly suggest that Ph-SD has the potential to be a therapeutic candidate in the treatment of NAFLD and can be carried forward for further clinical studies.
Collapse
Affiliation(s)
- Jyoti Chhimwal
- Pharmacology and Toxicology Laboratory, Dietetics and Nutrition Technology Division, CSIR-Institute of Himalayan Bioresource Technology (CSIR-IHBT), Palampur 176061, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India.
| | - Rakesh Kumar Dhritlahre
- Formulation Laboratory, Dietetics and Nutrition Technology Division, CSIR-Institute of Himalayan Bioresource Technology (CSIR-IHBT), Palampur 176061, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India.
| | - Prince Anand
- Pharmacology and Toxicology Laboratory, Dietetics and Nutrition Technology Division, CSIR-Institute of Himalayan Bioresource Technology (CSIR-IHBT), Palampur 176061, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India.
| | - Ruchika
- Formulation Laboratory, Dietetics and Nutrition Technology Division, CSIR-Institute of Himalayan Bioresource Technology (CSIR-IHBT), Palampur 176061, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India.
| | - Vikram Patial
- Pharmacology and Toxicology Laboratory, Dietetics and Nutrition Technology Division, CSIR-Institute of Himalayan Bioresource Technology (CSIR-IHBT), Palampur 176061, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India.
| | - Ankit Saneja
- Formulation Laboratory, Dietetics and Nutrition Technology Division, CSIR-Institute of Himalayan Bioresource Technology (CSIR-IHBT), Palampur 176061, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India.
| | - Yogendra S Padwad
- Pharmacology and Toxicology Laboratory, Dietetics and Nutrition Technology Division, CSIR-Institute of Himalayan Bioresource Technology (CSIR-IHBT), Palampur 176061, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India.
| |
Collapse
|
3
|
Guo Z, Afza R, Moneeb Khan M, Khan SU, Khan MW, Ali Z, Batool S, Din FU. Investigation of the treatment potential of Raloxifene-loaded polymeric nanoparticles in osteoporosis: In-vitro and in-vivo analyses. Heliyon 2023; 9:e20107. [PMID: 37810010 PMCID: PMC10559869 DOI: 10.1016/j.heliyon.2023.e20107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2023] [Revised: 08/23/2023] [Accepted: 09/12/2023] [Indexed: 10/10/2023] Open
Abstract
Osteoporosis (OP), is a systemic bone disorder associated with low bone mass and bone tissue corrosion. Worsening of the disease condition leads to bone delicacy and fracture. Various drugs are available for the treatment of OP, however they have limitations including poor solubility, bioavailability and toxicity. Herein, Raloxifene-loaded polymeric nanoparticles (RLX-PNPs) were developed and investigated for the treatment of OP with possible solutions to the above mentioned problems. RLX-PNPs were prepared by modified ionic gelation method followed by determining their particle properties. FTIR, DSC and PXRD analysis of the RLX-PNPs were performed to check chemical interaction, thermal behavior and crystallinity, respectively. In-vitro release profile of RLX-PNPs was checked in lab setting, whereas its pharmacokinetics was investigated in Sprague-Dawley rats, in-vivo. Finally, the treatment potential of RLX-PNPs was analyzed in OP induced animal model. The optimized PNPs formulation indicated 134.5 nm particle size, +24.4 mV charge and 91.73% % EE. TEM analysis showed spherical and uniform sized particles with no interactions observed in FTIR analysis. In-vitro release of RLX from RLX-PNPs showed more sustained release behavior as compared to RLX-suspension. Moreover, pharmacokinetic investigations showed a significantly enhanced bioavailability of the RLX-PNPs as well as reduced serum levels of alkaline phosphatase and calcium in OP induced rats when compared with RLX-Suspension after oral administration. Findings of this study suggested that the developed RLX-PNPs have the potential to treat OP due to sustained release and improved bioavailability of the incorporated drug.
Collapse
Affiliation(s)
- Zhonghua Guo
- Department of Orthopaedics, Henan Province Hospital of TCM, Zhengzhou City, Henan Province, 450002, China
| | - Rabia Afza
- Department of Botany, Hazara University Mansehra KP, Pakistan
| | - Muhammad Moneeb Khan
- Department of Pharmacy Quaid-i-Azam University, 45320, Islamabad, Pakistan
- Nanomedicine Research Group, Department of Pharmacy Quaid-i-Azam University, 45320, Islamabad, Pakistan
| | - Saif Ullah Khan
- Institute of Biotechnology and Microbiology, Bacha Khan University, Charsada, KPK, Pakistan
| | - Muhammad Waseem Khan
- Institute of Pharmaceutical Sciences Khyber Medical University, Peshawar, Pakistan
| | - Zakir Ali
- Department of Pharmacy Quaid-i-Azam University, 45320, Islamabad, Pakistan
- Nanomedicine Research Group, Department of Pharmacy Quaid-i-Azam University, 45320, Islamabad, Pakistan
| | - Sibgha Batool
- Department of Pharmacy Quaid-i-Azam University, 45320, Islamabad, Pakistan
- Nanomedicine Research Group, Department of Pharmacy Quaid-i-Azam University, 45320, Islamabad, Pakistan
| | - Fakhar ud Din
- Department of Pharmacy Quaid-i-Azam University, 45320, Islamabad, Pakistan
- Nanomedicine Research Group, Department of Pharmacy Quaid-i-Azam University, 45320, Islamabad, Pakistan
| |
Collapse
|
4
|
Imran B, Din FU, Ali Z, Fatima A, Khan MW, Kim DW, Malik M, Sohail S, Batool S, Jawad M, Shabbir K, Zeb A, Khan BA. Statistically designed dexibuprofen loaded solid lipid nanoparticles for enhanced oral bioavailability. J Drug Deliv Sci Technol 2022. [DOI: 10.1016/j.jddst.2022.103904] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
5
|
Tran P, Park JS. Formulation of solid dispersion to improve dissolution and oral bioavailability of poorly soluble dexibuprofen. Pharm Dev Technol 2021; 26:422-430. [PMID: 33543664 DOI: 10.1080/10837450.2021.1884259] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
Dexibuprofen (DEXI) belongs to BCS class II drug with poor aqueous solubility resulting in poor bioavailability. To enhance solubility and bioavailability of DEXI, DEXI-loaded solid dispersion (SD) was formulated. DEXI-SDs were prepared by melting method and solvent evaporation method. Amphipathic polymer poloxamer 407 (pol 407) was selected based on solubility and dissolution tests. The ratio of DEXI:pol 407 was optimized as 1:2. The physicochemical properties, dissolution, and oral bioavailability of SD3 and SD6 were evaluated to compare preparation methods. The dissolution rate of DEXI from SD formulations was higher at pH 6.8 and pH 7.2 than at pH 1.2. Following oral administration in rats, the Cmax and AUClast of SD3 and SD6 formulations were significantly higher compared with raw DEXI. In addition, the SD6 formulation showed increased Cmax and AUClast by 1.34- and 1.33-fold, compared with those of SD3 formulation, respectively. These results demonstrated that SD formulation has excellent potential as a formulation for poorly soluble drug DEXI.
Collapse
Affiliation(s)
- Phuong Tran
- College of Pharmacy, Chungnam National University, Daejeon, Korea
| | - Jeong-Sook Park
- College of Pharmacy, Chungnam National University, Daejeon, Korea
| |
Collapse
|